Background: TNMBC is an aggressive BC subtype with few treatment options. Phase II trials have demonstrated efficacy and tolerability of nab-P-containing regimens for TNMBC. The international triple-negative Albumin-bound paclitaxel combination treatment study (tnAcity) will examine 2 nab-P regimens (with either Gem or Carbo) and compare the selected regimen with Gem/Carbo as first-line treatment for TNMBC. Trial design: All patients must have TNMBC (TN defined as ER and PgR expression < 1% by IHC and HER2 0 -1+ by IHC or confirmed negative by FISH). Pts will be enrolled in North America, Europe, Latin America, and Australia. In the phase II portion, 240 pts will receive nab-P 125 mg/m 2 plus Gem 1000 mg/m 2 (arm A), nab-P 125 mg/m 2 plus Carbo area under the curve (AUC) 2 (arm B), or the control regimen of Gem 1000 mg/m 2 plus Carbo AUC 2 (arm C), all given intravenously on days 1 and 8 of a 21-day cycle. Eligibility criteria include no prior cytotoxic therapy for MBC, prior adjuvant or neoadjuvant anthracycline use unless not indicated, and no history or current evidence of brain metastasis. Adjuvant taxane-, Gem-, or platinum-containing regimens must have been completed ≥ 12 mo before randomization (6 mo for all others). The phase II portion will identify the nab-P combination to be evaluated in the phase III portion based on efficacy and safety. In the phase III portion, 550 pts will receive the selected nab-P regimen (A or B) or Gem/ Carbo. The trial design provides ≈ 90% power to detect a hazard ratio of 0.70 for progression-free survival (PFS).Previous publication : SABCS 2013 [OT3-1-11] 
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